A Probody T Cell-Engaging Bispecific Antibody Targeting EGFR and CD3 Inhibits Colon Cancer Growth with Limited Toxicity.

Leila M Boustany,Sherry L LaPorte, Laurie Wong,Clayton White,Veena Vinod,Joel Shen,Wendy Yu,David Koditek,Michael B Winter,Stephen J Moore,Li Mei,Linnea Diep, Yuanhui Huang,Shouchun Liu,Olga Vasiljeva,Jim West,Jennifer Richardson,Bryan Irving,Marcia Belvin,W Michael Kavanaugh

Cancer research（2022）

引用 8|浏览4

暂无评分

摘要

A conditionally active EGFR-CD3 T cell-engaging Probody therapeutic expands the safety window of bispecific antibodies while maintaining efficacy in preclinical solid tumor settings.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要